The lowering of the price target by Morgan Stanley could potentially lead to a decrease in Moderna's stock price in the short term as it indicates a lower valuation for the company. The Equal-Weight rating suggests that the stock is expected to perform in line with the market, which may not be enough to counteract the negative impact of the lowered price target.